Brentuximab vedotin + AVD (Doxorubicin, Vinblastine, Dacarbazine)
Treatment for Hodgkin Lymphoma
Typical Dosage: Brentuximab vedotin 1.2 mg/kg, Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, Dacarbazine 375 mg/m2, on days 1 & 15 of 21-day cycles
Effectiveness
88%
Safety Score
30%
Clinical Trials
19
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
Brentuximab vedotin 1.2 mg/kg, Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, Dacarbazine 375 mg/m2, on days 1 & 15 of 21-day cycles
Time to Effect
Weeks to months
Treatment Duration
6 months
Evidence Quality
HIGHNumber Needed to Treat (NNT)
14(Treat 14 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
11(Treat 11 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150,000
Monitoring:$10,000
Side Effect Mgmt:$7,500
Total Annual:$167,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$197,295/QALY
QALYs Gained
26
Outcome-Based Costs
Cost per Responder
$186,111
Cost per Remission
$223,333
Comparison vs ABVD
Cost Difference
+$138,000/year
More expensive
QALY Difference
+1.00 QALYs
Better outcomes
Dominance
No dominance
Brentuximab vedotin + AVD (Doxorubicin, Vinblastine, Dacarbazine) Outcomes
for Hodgkin Lymphoma
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+90%
Remission Rate
+75%
Common Side Effects
Peripheral Neuropathy
+55%
Neutropenia
+45%
Fatigue
+35%
Nausea
+35%
Hair Loss
+35%
Sources:
Active Clinical Trials
9 active trials recruiting for Brentuximab vedotin + AVD (Doxorubicin, Vinblastine, Dacarbazine) in Hodgkin Lymphoma
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
NCT02979522ACTIVE NOT RECRUITINGPHASE1, PHASE2
59 participants
INTERVENTIONAL
Aurora, United States +13 more
Started: Sep 6, 2017
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
NCT06377566RECRUITINGPHASE2
71 participants
INTERVENTIONAL
Miami, United States +7 more
Started: Apr 17, 2024
Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above
NCT05404945ACTIVE NOT RECRUITINGPHASE2
24 participants
INTERVENTIONAL
New Brunswick, United States +2 more
Started: Jul 26, 2022
A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma
NCT05481437RECRUITING
8 participants
OBSERVATIONAL
Tokyo, Japan
Started: Aug 1, 2022
Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
NCT03233347ACTIVE NOT RECRUITINGPHASE2
83 participants
INTERVENTIONAL
Duarte, United States +8 more
Started: Oct 13, 2017
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
NCT05253495RECRUITINGPHASE2
80 participants
INTERVENTIONAL
Birmingham, United States +2 more
Started: Feb 1, 2022
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
NCT03712202ACTIVE NOT RECRUITINGPHASE2
155 participants
INTERVENTIONAL
Birmingham, United States +16 more
Started: Nov 28, 2018
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
NCT03907488ACTIVE NOT RECRUITINGPHASE3
994 participants
INTERVENTIONAL
Birmingham, United States +727 more
Started: Aug 29, 2019
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
NCT05675410RECRUITINGPHASE3
1.88K participants
INTERVENTIONAL
Birmingham, United States +414 more
Started: May 11, 2023
Completed Clinical Trials
8 completed trials for Brentuximab vedotin + AVD (Doxorubicin, Vinblastine, Dacarbazine) in Hodgkin Lymphoma
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
NCT01534078COMPLETEDPHASE2
34 participants
INTERVENTIONAL
Tampa, United States +3 more
Started: Mar 1, 2012
Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
NCT07171827COMPLETEDNA
60 participants
INTERVENTIONAL
Helwan, Egypt
Started: Mar 1, 2023
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
NCT01712490COMPLETEDPHASE3
1.33K participants
INTERVENTIONAL
Birmingham, United States +214 more
Started: Nov 9, 2012
A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma
NCT01060904COMPLETEDPHASE1
51 participants
INTERVENTIONAL
Rochester, United States +3 more
Started: Jan 1, 2010
Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
NCT01868451COMPLETEDNA
118 participants
INTERVENTIONAL
Duarte, United States +9 more
Started: May 1, 2013
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.
NCT02292979COMPLETEDPHASE2
170 participants
INTERVENTIONAL
Antwerp, Belgium +64 more
Started: Mar 1, 2015
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma
NCT01771107COMPLETEDPHASE1, PHASE2
41 participants
INTERVENTIONAL
La Jolla, United States +27 more
Started: Mar 8, 2013
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
NCT01476410COMPLETEDPHASE2
49 participants
INTERVENTIONAL
Stanford, United States +6 more
Started: Nov 1, 2011